Market capitalization | $94.18m |
Enterprise Value | $72.45m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 724.50 |
P/S ratio (TTM) P/S ratio | 941.80 |
P/B ratio (TTM) P/B ratio | 1.88 |
Revenue (TTM) Revenue | $100.00k |
EBIT (operating result TTM) EBIT | $-81.30m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Fractyl Health forecast:
3 Analysts have issued a Fractyl Health forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.10 0.10 |
-
|
|
Gross Profit | -0.45 -0.45 |
-
|
|
EBITDA | -81 -81 |
-
|
EBIT (Operating Income) EBIT | -81 -81 |
-
|
Net Profit | -63 -63 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.
Head office | United States |
CEO | Harith Rajagopalan |
Founded | 2010 |
Website | www.fractyl.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.